BRAF-mutated tumors, particularly those harboring a V600E mutation, are associated with significantly poorer OS than BRAF-V600 wild-type tumors (median 10.4 versus 34.7 months), and a higher rate of peritoneal and distant lymph node metastasis [27]. The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.